echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Research Frontier ARAMIS trial results update: treatment of nmCRPC patients, darolutamide can be expected in the future!

    Research Frontier ARAMIS trial results update: treatment of nmCRPC patients, darolutamide can be expected in the future!

    • Last Update: 2023-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit



    Patients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at
    high risk of disease progression and metastasis.
    Recently, the results of an important subgroup analysis of the phase III ARAMIS trial were announced, what is the efficacy and safety of darolutamide in this type of patient? The editor has compiled the following for the reader

    Research background

    Evidence suggests that shorter PSADT predicts a higher risk of disease progression and metastasis
    PSADT<6 months is generally considered the cut-off for patients to receive more aggressive therapy, and international evidence-based guidelines recommend that patients with PSADT ≤ 10 months should be treated<b11> with standard androgen deprivation therapy (ADT) plus a new-generation androgen receptor inhibitor (ARI).
    Therefore, the ARAMIS trial stratified patients with nmCRPC according to PSADT (PSADT≤ 6 months; 6< PSADT ≤10 months) to assess the efficacy and safety<b12> of darolutamide compared to placebo in different subgroups of patients with PSADT.

    Study design

    ARAMIS (NCT02200614) is a global, multicenter, double-blind, randomized phase III trial in patients with nmCRPC with PSADT ≤ 10 months
    Patients were randomized 2:1 to darolutamide and placebo and received ADT + darolutamide (600 mg orally twice daily) and ADT+ placebo
    , respectively.
    The primary endpoint was metastasis-free survival (MFS), and the secondary endpoints were overall survival (OS), time to pain progression, time to first chemotherapy administration, and time to first symptomatic skeletal event (SSE), while quality of life (QoL) and safety
    were also assessed.

    Study results

    Of the 1509 enrolled patients, 469 had PSADT > 6 months (n=286 in the darolutamide group; n=183 in the placebo group) and PSADT ≤ 6 months in 1040 patients (n=669 in the darolutamide group; n=371 in the placebo group).

    The baseline characteristics of patients were approximately the same between the
    two subgroups.

    Compared with placebo, darolutamide significantly prolonged the patient's MFS
    In the PSADT > 6-month group, the risk of disease metastasis or death was significantly reduced by 62% (HR = 0.
    38, 95% CI 0.
    26 to 0.
    55); In the PSADT ≤ 6-month group, the risk of disease metastasis or death was reduced by 59% (HR = 0.
    41, 95% CI 0.
    33 to 0.

    Figure 1 Kaplan-Meier survival curve of MFS and OS for subgroups by PSADT

    Compared to placebo, darolutamide significantly prolonged the patient's OS
    The risk of death was reduced by 45% in the PSADT>6-month group (p=0.
    01) compared with 26% (p=0.
    in the PSADT≤6-month group.

    Other efficacy endpoints (time to pain progression, time to first chemotherapy, SSE, and progression-free survival) and QoL endpoint analysis showed significant improvement
    in patients treated with darolutamide in both subgroups compared with placebo.
    Patients had a lower incidence of treatment-related adverse events (including ADT-related adverse events or discontinuation due to adverse events), and darolutamide was similar
    to placebo in terms of safety outcomes.

    Conclusion of the study

    Darolutamide showed good efficacy and tolerability in patients with nmCRPC >at 6 months (≤ 10 months) of PSADT, significantly improved MFS, OS, and other clinically relevant outcomes, and maintained QoL


    Bögemann M, Shore ND, Smith MR, et al.
    Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Eur Urol.
    2022 Sep 8:S0302-2838(22)02532-5.
    doi: 10.
    Epub ahead of print.
    PMID: 36089529.

    Editor: Wang Mumu Reviewed: LR Executive: Wang Mumu

    This platform is designed to deliver more medical information
    to healthcare professionals.
    The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
    If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
    The content published by this platform does not mean that it agrees with its description and views
    If copyright issues are involved, please contact us and we will deal with
    it as soon as possible.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.